A follow-on study of high dose levels of entolimod in patients with advanced cancers in Russia.

Trial Profile

A follow-on study of high dose levels of entolimod in patients with advanced cancers in Russia.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Apr 2015

At a glance

  • Drugs Entolimod (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 27 Apr 2015 Status changed from not yet recruiting to recruiting based on a Cleveland BioLabs media release.
    • 27 Apr 2015 As per a Cleveland BioLabs media release, this trial will be supported by a part of a $1.2 million Breast Cancer Research Program Breakthrough Award to the Roswell Park Cancer Institute by the Department of Defence Congressionally Directed Medical Research Program.
    • 10 Feb 2015 According to Cleveland Biolabs Inc media release, the company has initiated a follow-on study in Moscow, Russia, which is financially supported by the Ministry of Industry and Trade of the Russian Federation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top